Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

An expert discusses the current understanding of corticosteroids in managing pulmonary fibrosis and how it has evolved in ...

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...

The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a $1.03 billion market cap biotech company, executed sales of common stock valued at a total of $46,360 over two consecutive days, ...